Minos Biosciences

Minos is a French deep-tech start-up aiming to revolutionise our understanding of complex diseases such as cancer, infectious and autoimmune diseases. By offering a breakthrough, yet affordable, adaptable, easy-to-use, all-in-one platform, Minos’ solution allows researchers to link a cell’s dynamic, phenotypic behaviour to its OMIC profile, gleaning unprecedentedly accurate and comprehensive insights into phenotype-genotype interactions at a single cell level. Unlike existing technologies, our platform allows linking genomic, transcriptomic, and epigenetic profiles of hundreds of thousands of cells to their individual phenotype and behaviour. We will offer a variety of cellular profiling assays that allow the functional and dynamic characterization of cells from the same sample, allowing a deeper understanding of cell behaviour, heterogenous drug responses, host-pathogen interactions, which are central to improving therapeutics in the aforementioned fields, especially in the precision medicine space.

Beyond the scientific community, our technology will revolutionise R&D in the pharmaceutical industry by allowing a comprehensive and actionable understanding of drugs’ mechanism of action and drug resistance at an individual patient level by integrating genomic, epigenomic, transcriptomic and cell behavioural data. In biotech, our technology can be used in a multitude of ways, notably for target validation and drug discovery, including vaccine based as well as cell and gene therapies. Long-term, this will help inform the development and choice of precision medicines that bypass drug resistance pathways with fewer side effects. Similarly, our technology will enable next-generation diagnostics which we anticipate being as disruptive as genomics has been in this space.